Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma.

Chahoud J, Sui D, Erwin WD, Gulbis AM, Korbling M, Zhang M, Ahmed S, Alatrash G, Anderlini P, Ciurea SO, Oran B, Fayad LE, Bassett RL Jr, Jabbour EJ, Medeiros LJ, Macapinlac HA, Young KH, Khouri IF.

Clin Cancer Res. 2018 May 15;24(10):2304-2311. doi: 10.1158/1078-0432.CCR-17-3561. Epub 2018 Feb 23.

2.

Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion.

Oran B, Saliba RM, Carmazzi Y, de Lima M, Rondon G, Ahmed S, Alousi A, Andersson BS, Anderlini P, Alvarez M, Bashir Q, Ciurea S, Fernandez-Vina M, Hosing C, Kebriaei P, Korbling M, Cano P, Khouri I, Marin D, Nieto Y, Olson A, Popat U, Rezvani K, Qazilbash M, Shpall EJ, Champlin RE, Cao K.

Blood. 2018 Mar 15;131(11):1248-1257. doi: 10.1182/blood-2017-07-798751. Epub 2018 Jan 31.

3.

Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation.

Khouri MR, Jabbour EJ, Gulbis AM, Turturro F, Ledesma C, Korbling M, Samuels BI, Ahmed S, Alousi AM, Ciurea SO, Marin D, Patel KK, Popat UR, Bueso-Ramos CE, Bassett RL Jr, Khouri IF.

Biol Blood Marrow Transplant. 2017 Aug;23(8):1405-1410. doi: 10.1016/j.bbmt.2017.04.027. Epub 2017 May 8.

4.

Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.

Bock F, Lu G, Srour SA, Gaballa S, Lin HY, Baladandayuthapani V, Honhar M, Stich M, Shah ND, Bashir Q, Patel K, Popat U, Hosing C, Korbling M, Delgado R, Rondon G, Shah JJ, Thomas SK, Manasanch EE, Isermann B, Orlowski RZ, Champlin RE, Qazilbash MH.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2159-2164. doi: 10.1016/j.bbmt.2016.09.003. Epub 2016 Sep 13.

5.

Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.

Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO.

Cancer. 2016 Nov 15;122(21):3316-3326. doi: 10.1002/cncr.30180. Epub 2016 Jul 12.

6.

Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease.

Beitinjaneh A, Saliba RM, Medeiros LJ, Turturro F, Rondon G, Korbling M, Fayad L, Fanale MA, Alousi AM, Anderlini P, Betul O, Popat UR, Pro B, Khouri IF.

Biol Blood Marrow Transplant. 2015 May;21(5):855-9. doi: 10.1016/j.bbmt.2015.01.013. Epub 2015 Jan 31.

7.

BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD.

Khouri IF, Wei W, Korbling M, Turturro F, Ahmed S, Alousi A, Anderlini P, Ciurea S, Jabbour E, Oran B, Popat UR, Rondon G, Bassett RL Jr, Gulbis A.

Blood. 2014 Oct 2;124(14):2306-12. doi: 10.1182/blood-2014-07-587519. Epub 2014 Aug 21.

8.

Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis.

Poon ML, Fox PS, Samuels BI, O'Brien S, Jabbour E, Hsu Y, Gulbis A, Korbling M, Champlin R, Abruzzo LV, Bassett RL, Khouri IF.

Leuk Lymphoma. 2015 Mar;56(3):711-5. doi: 10.3109/10428194.2014.930848. Epub 2014 Aug 4.

9.

Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission.

Chakhachiro ZI, Saliba RM, Okoroji GJ, Korbling M, Alousi AM, Betul O, Anderlini P, Ciurea SO, Popat U, Champlin R, Samuels BI, Medeiros LJ, Bueso-Ramos C, Khouri IF.

Cancer. 2013 Sep 15;119(18):3318-25. doi: 10.1002/cncr.28219. Epub 2013 Jun 17.

10.

Cord-blood engraftment with ex vivo mesenchymal-cell coculture.

de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ.

N Engl J Med. 2012 Dec 13;367(24):2305-15. doi: 10.1056/NEJMoa1207285.

11.

Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.

Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE.

Biol Blood Marrow Transplant. 2012 Dec;18(12):1835-44. doi: 10.1016/j.bbmt.2012.07.003. Epub 2012 Jul 11.

12.

Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.

Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA.

Blood. 2012 Jun 28;119(26):6373-8. doi: 10.1182/blood-2012-03-417808. Epub 2012 May 14.

13.

Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation.

Ciurea SO, Thall PF, Wang X, Wang SA, Hu Y, Cano P, Aung F, Rondon G, Molldrem JJ, Korbling M, Shpall EJ, de Lima M, Champlin RE, Fernandez-Vina M.

Blood. 2011 Nov 24;118(22):5957-64. doi: 10.1182/blood-2011-06-362111. Epub 2011 Oct 3.

14.

Twenty-five years of peripheral blood stem cell transplantation.

Körbling M, Freireich EJ.

Blood. 2011 Jun 16;117(24):6411-6. doi: 10.1182/blood-2010-12-322214. Epub 2011 Apr 1. Review.

PMID:
21460243
15.

A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin's lymphomas.

Hosing C, Munsell MF, Reuben JM, Popat U, Lee BN, Gao H, Körbling M, Shpall EJ, Kebriaei P, Alousi A, De Lima M, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I.

J Blood Med. 2010;1:49-55. doi: 10.2147/JBM.S9846. Epub 2010 Apr 14.

16.

High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation.

Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ, Wang X, Thall PF, Champlin RE, Fernandez-Vina M.

Transplantation. 2009 Oct 27;88(8):1019-24. doi: 10.1097/TP.0b013e3181b9d710.

17.

Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.

Ciurea SO, Saliba R, Rondon G, Pesoa S, Cano P, Fernandez-Vina M, Qureshi S, Worth LL, McMannis J, Kebriaei P, Jones RB, Korbling M, Qazilbash M, Shpall EJ, Giralt S, de Lima M, Champlin RE, Gajewski J.

Bone Marrow Transplant. 2010 Mar;45(3):429-36. doi: 10.1038/bmt.2009.189. Epub 2009 Aug 10.

18.

Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.

Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S.

Biol Blood Marrow Transplant. 2009 Jun;15(6):718-23. doi: 10.1016/j.bbmt.2009.02.011. Epub 2009 Apr 8.

19.

Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma.

Hosing C, Saliba RM, Ahlawat S, Körbling M, Kebriaei P, Alousi A, De Lima M, Okoroji JG, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I, Popat U.

Am J Hematol. 2009 Jun;84(6):335-7. doi: 10.1002/ajh.21400.

20.

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.

Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C, Kebraei P, Harrell R, Rondon G, Giralt SA, Anderlini P, Popat U, Pro B, Samuels B, Hagemeister F, Medeiros LJ, Champlin RE, Khouri IF.

Blood. 2009 Apr 30;113(18):4144-52. doi: 10.1182/blood-2008-10-184200. Epub 2009 Jan 23.

21.

Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation.

Alousi AM, Saliba RM, Okoroji GJ, Macapinlac HA, Hosing C, Korbling M, Samuels BI, Popat U, Kebriaei P, Anderlini P, Qazilbash MH, de Lima M, Giralt SA, Champlin RE, Khouri IF.

Br J Haematol. 2008 Sep;142(5):786-92. doi: 10.1111/j.1365-2141.2008.07277.x. Epub 2008 Jun 17.

PMID:
18564354
22.

Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.

Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, Roberson S, Giralt S, Pierre B, Russell JA, Shpall EJ, Jones RB, Champlin RE.

Biol Blood Marrow Transplant. 2008 Jun;14(6):672-84. doi: 10.1016/j.bbmt.2008.03.009.

23.

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.

Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE.

Blood. 2008 Jun 15;111(12):5530-6. doi: 10.1182/blood-2008-01-136242. Epub 2008 Apr 14. Erratum in: Blood. 2009 Feb 12;113(7):1613.

24.

Fusion of circulating blood cells with solid-organ tissue cells in clinical stem cell transplants: a potential therapeutic model?

Körbling M, de Lima MJ, Thomas E, Khanna A, Najjar AM, Gu J, Gelovani JG, Broaddus R.

Regen Med. 2008 Mar;3(2):157-64. doi: 10.2217/17460751.3.2.157.

25.

Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia.

Khouri IF, Saliba RM, Admirand J, O'Brien S, Lee MS, Korbling M, Samuels BI, Giralt S, Lima de M, Keating MJ, Champlin RE, Bueso-Ramos C.

Br J Haematol. 2007 May;137(4):355-63.

PMID:
17456058
26.

Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment.

Oran B, Donato M, Aleman A, Hosing C, Korbling M, Detry MA, Wei C, Anderlini P, Popat U, Shpall E, Giralt S, Champlin RE.

Biol Blood Marrow Transplant. 2007 Apr;13(4):469-77. Epub 2007 Feb 8.

27.

Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis.

Körbling M, Reuben JM, Gao H, Lee BN, Harris DM, Cogdell D, Giralt SA, Khouri IF, Saliba RM, Champlin RE, Zhang W, Estrov Z.

Transfusion. 2006 Oct;46(10):1795-802.

PMID:
17002637
28.

High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma.

Hosing C, Saliba RM, Körbling M, Acholonu S, McMannis J, Anderlini P, Giralt S, De Lima M, Okoroji GJ, Couriel DR, Champlin R, Khouri IF, Donato ML.

Leuk Lymphoma. 2006 Jul;47(7):1290-4.

PMID:
16923559
29.

Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.

Lekakis L, Giralt S, Couriel D, Shpall EJ, Hosing C, Khouri IF, Anderlini P, Korbling M, Martin T, Champlin RE, de Lima M.

Bone Marrow Transplant. 2006 Sep;38(6):421-6. Epub 2006 Aug 7.

PMID:
16892072
30.

Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma.

Hosing C, Qazilbash MH, Kebriaei P, Giralt S, Davis MS, Popat U, Anderlini P, Shpall EJ, McMannis J, Körbling M, Champlin RE.

Br J Haematol. 2006 Jun;133(5):533-7.

PMID:
16681642
31.

The effect of low dose gamma irradiation on the differentiation and maturation of monocyte derived dendritic cells.

Reuben JM, Korbling M, Gao H, Lee BN.

J Gravit Physiol. 2004 Jul;11(2):P49-52.

PMID:
16231453
32.

Circulating endothelial progenitor cells and coronary collaterals in patients with non-ST segment elevation myocardial infarction.

Lev EI, Kleiman NS, Birnbaum Y, Harris D, Korbling M, Estrov Z.

J Vasc Res. 2005 Sep-Oct;42(5):408-14. Epub 2005 Aug 8.

PMID:
16088214
33.

Umbilical cord blood-derived cells for tissue repair.

Körbling M, Robinson S, Estrov Z, Champlin R, Shpall E.

Cytotherapy. 2005;7(3):258-61. Review.

PMID:
16081352
34.

Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.

Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, Couriel D, De Lima M, Donato ML, Fayad L, Giralt S, Jones R, Korbling M, Maadani F, Manning JT, Pro B, Shpall E, Younes A, McLaughlin P, Champlin RE.

J Clin Oncol. 2005 Apr 1;23(10):2240-7.

PMID:
15800314
35.

A mathematical model of haemopoiesis as exemplified by CD34 cell mobilization into the peripheral blood.

Obeyesekere MN, Berry RW, Spicer PP, Korbling M.

Cell Prolif. 2004 Aug;37(4):279-94.

PMID:
15245564
36.

Circulating stem cells and tissue repair.

Hennessy B, Körbling M, Estrov Z.

Panminerva Med. 2004 Mar;46(1):1-11. Review.

37.

Designing an ethical policy for bone marrow donation by minors and others lacking capacity.

Pentz RD, Chan KW, Neumann JL, Champlin RE, Korbling M.

Camb Q Healthc Ethics. 2004 Spring;13(2):149-55. No abstract available.

PMID:
15124402
38.

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, Shpall EJ, Shahjahan M, Pierre B, Giralt S, Korbling M, Russell JA, Champlin RE, Andersson BS.

Blood. 2004 Aug 1;104(3):857-64. Epub 2004 Apr 8.

PMID:
15073038
39.

Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival.

Monaco G, Konopleva M, Munsell M, Leysath C, Wang RY, Jackson CE, Korbling M, Estey E, Belmont J, Andreeff M.

Stem Cells. 2004;22(2):188-201.

40.

Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival.

Khouri IF, Lee MS, Saliba RM, Andersson B, Anderlini P, Couriel D, Hosing C, Giralt S, Korbling M, McMannis J, Keating MJ, Champlin RE.

Exp Hematol. 2004 Jan;32(1):28-35.

PMID:
14725898
41.

Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo.

Yeh ET, Zhang S, Wu HD, Körbling M, Willerson JT, Estrov Z.

Circulation. 2003 Oct 28;108(17):2070-3. Epub 2003 Oct 20.

PMID:
14568894
42.

Adult stem cells and tissue repair.

Körbling M, Estrov Z, Champlin R.

Bone Marrow Transplant. 2003 Aug;32 Suppl 1:S23-4. Review.

PMID:
12931235
43.

Adult stem cells for tissue repair - a new therapeutic concept?

Kørbling M, Estrov Z.

N Engl J Med. 2003 Aug 7;349(6):570-82. Review. No abstract available.

PMID:
12904523
44.

Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel.

Duzkale H, Pagliaro LC, Rosenblum MG, Varan A, Liu B, Reuben J, Wierda WG, Korbling M, McMannis JD, Glassman AB, Scheinberg DA, Freireich EJ.

Biol Blood Marrow Transplant. 2003 Jun;9(6):364-72.

45.

Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.

Apisarnthanarax N, Donato M, Körbling M, Couriel D, Gajewski J, Giralt S, Khouri I, Hosing C, Champlin R, Duvic M, Anderlini P.

Bone Marrow Transplant. 2003 Mar;31(6):459-65.

PMID:
12665841
46.

Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units.

De Lima M, St John LS, Wieder ED, Lee MS, McMannis J, Karandish S, Giralt S, Beran M, Couriel D, Korbling M, Bibawi S, Champlin R, Komanduri KV.

Br J Haematol. 2002 Dec;119(3):773-6.

PMID:
12437658
47.

Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization.

Gajewski JL, Rondon G, Donato ML, Anderlini P, Korbling M, Ippoliti C, Benyunes M, Miller LL, LaTemple D, Jones D, Ashby M, Hellmann S, Durett A, Lauppe J, Geisler D, Khouri IF, Giralt SA, Andersson B, Ueno NT, Champlin R.

Biol Blood Marrow Transplant. 2002;8(10):550-6.

48.

Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia development.

Anderlini P, Chan FA, Champlin RE, Körbling M, Strom SS.

Bone Marrow Transplant. 2002 Nov;30(10):661-3.

49.

Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.

Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P, Molldrem J, Ueno NT, Donato M, Korbling M, Gajewski J, Alexanian R, Champlin R.

Bone Marrow Transplant. 2002 Sep;30(6):367-73.

50.

Marginal keratitis associated with administration of filgrastim and sargramostim in a healthy peripheral blood progenitor cell donor.

Esmaeli B, Ahmadi MA, Kim S, Onan H, Korbling M, Anderlini P.

Cornea. 2002 Aug;21(6):621-2.

PMID:
12131046

Supplemental Content

Loading ...
Support Center